72 completed. 72 Phase 1, 23 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 72 | Completed 72 |
| Phase 2 | 23 | Completed 23 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Different Administration Routes of Dexmedetomidine on Postoperative Sleep Quality in Patients Undergoing Thyroidectomy Dexmedetomidine (DEX), Saline - Thyroid Diseases | Phase 1 / Phase 2 | Completed | The Second People's Hospital of Huai'an | 120 | 2026-01-05 | 2026-09-11 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants Teprotumumab, Placebo - Healthy Volunteers | Phase 1 | Completed | Amgen | 20 | 2025-08-26 | 2026-02-27 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Completed | Arvinas Inc. | 76 | 2025-05-29 | 2026-11-17 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery Oxidized regenerated cellulose(ORC), Hyaluronic acid(HA) - Thyroidectomy, Goiter | Phase 1 | Completed | National Taiwan University Hospital | 45 | 2023-05-24 | 2025-09-19 |
| Study of ZB001 in Chinese Patients With Thyroid Eye Disease ZB001 for injection - Thyroid Eye Disease | Phase 1 | Completed | Zenas BioPharma (USA), LLC | 17 | 2023-05-10 | 2025-04-11 |
| A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants Teprotumumab - Healthy Volunteers | Phase 1 | Completed | Amgen | 44 | 2023-03-24 | 2024-11-05 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) lonigutamab, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | ACELYRIN Inc. | 31 | 2023-02-14 | 2025-07-01 |
| Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg - Advanced Solid Tumor, Lung Cancer | Phase 1 | Completed | Sichuan Enray Pharmaceutical Sciences Company | 19 | 2022-11-17 | 2025-08-03 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease Teprotumumab - Thyroid Eye Disease | Phase 1 | Completed | Amgen | 16 | 2022-07-14 | 2024-06-21 |
| Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer 177Lu-DOTA-EB-FAPI 1 radionuclide therapy, 177Lu-DOTA-EB-FAPI 2 radionuclide therapy, 177Lu-DOTA-EB-FAPI 3 radionuclide therapy - Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma | Phase 1 | Completed | The First Affiliated Hospital of Xiamen University | 12 | 2022-06-15 | 2025-04-01 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | Lassen Therapeutics 1 PTY LTD | 75 | 2022-06-06 | 2024-12-30 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment LOXO-260 - Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 70 | 2022-03-23 | 2026-08-21 |
| Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW Bevacizumab-IRDye800CW - Thyroid Carcinoma, Surgery | Phase 1 | Completed | University Medical Center Groningen | 20 | 2021-11-29 | 2024-08-22 |
| Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer Targeted alpha therapy - Thyroid Cancer | Phase 1 | Completed | Osaka University | 11 | 2021-11-20 | 2025-04-24 |
| Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects MYMD-1, Placebo - Hashimoto Disease | Phase 1 | Completed | TNF Pharmaceuticals, Inc. | 32 | 2021-04-26 | 2023-03-27 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Famewave Ltd. | 79 | 2021-03-19 | 2024-12-27 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
Showing 20 of 72. Sign in to see all of them.
Thyroid Neoplasms (43) · Thyroid Cancer, Papillary (16) · Breast Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (14) · Head and Neck Neoplasms (14) · Melanoma (14) · Ovarian Neoplasms (14) · Prostatic Neoplasms (14) · Pancreatic Neoplasms (13) · Adenocarcinoma, Follicular (11) · Colonic Neoplasms (11) · Colorectal Neoplasms (11) · Lung Neoplasms (11) · Sarcoma (11) · Urinary Bladder Neoplasms (11)
Endocrine System Diseases (70) · Neoplasms by Site (49) · Endocrine Gland Neoplasms (48) · Neoplasms (41) · Head and Neck Neoplasms (36) · Neoplasms by Histologic Type (36) · Neoplasms, Glandular and Epithelial (33) · Carcinoma (31) · Adenocarcinoma (27) · Skin Diseases (24) · Skin and Connective Tissue Diseases (24) · Female Urogenital Diseases (22) · Female Urogenital Diseases and Pregnancy Complications (22) · Lung Diseases (22)
teprotumumab (4) · Iodine-131 (3) · Triiodothyronine (3) · Azacitidine (2) · Injections (2) · Methimazole (2) · Paclitaxel (2) · Rituximab (2) · Thyrotropin Alfa (2) · Trastuzumab (2) · Vemurafenib (2) · belinostat (2) · pazopanib (2) · 1-phenyl-3,3-dimethyltriazene (1) · 130-nm albumin-bound paclitaxel (1)
National Cancer Institute (NCI) (5) · Amgen (4) · Exelixis (3) · Memorial Sloan Kettering Cancer Center (3) · European Organisation for Research and Treatment of Cancer - EORTC (2) · TNF Pharmaceuticals, Inc. (2) · TransThera Sciences (Nanjing), Inc. (2) · University Medical Center Groningen (2) · University of Pennsylvania (2) · Valerio Therapeutics (2) · ACELYRIN Inc. (1) · AHS Cancer Control Alberta (1) · AV7 Limited (1) · Alume Biosciences, Inc. (1) · Apitope International NV (1)
United States (47) · China (10) · Netherlands (5) · United Kingdom (5) · Canada (4) · Denmark (3) · France (3) · Germany (3) · Spain (3) · Australia (2) · Belgium (2) · Hong Kong (2) · South Korea (2) · Taiwan (2) · Egypt (1)
Anne R Cappola, MD,ScM (2) · Alan L Ho, MD, PhD (1) · Alexander McEwan, MB, FCRPC (1) · Anthony W. Tolcher, MD (1) · Art Simon, PhD (1) · Chih-Yi Liao (1) · Christopher R McHenry, MD (1) · Cornelis J. A. Punt, MD, PhD (1) · Dan Liang, MD (1) · Daniel El-Fassi, MD (1) · Dave Singh, Professor (1) · Du Lam, MD (1) · Edward S. Kim, MD (1)
PMID 17985341, PMID 19192962, PMID 19372041, PMID 19602035, PMID 19735988, PMID 19850691, PMID 20145168, PMID 21367608, PMID 21606412, PMID 22219499, PMID 23489023, PMID 23676418, PMID 23868427, PMID 24827131, PMID 26221138, PMID 27240885, PMID 28662033, PMID 28744123, PMID 29186019, PMID 30184767, PMID 32416981, PMID 32510916, PMID 34118197, PMID 34118198, PMID 34766118, PMID 35045748, PMID 35389070, PMID 35715405, PMID 35962206, PMID 37171634, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 38017325, PMID 39863139, PMID 40595556, PMID 40613790, PMID 40639400, PMID 41886723, PMID 42249319, PMID 42816483
2016 (2), R61HL146390 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), P30CA014599 (1), P30CA015704 (1), P30CA043703 (1), P30CA072720 (1), U01CA062502 (1), U01CA062505 (1), U01CA069912 (1)